Immunome Inc

IMNM

Healthcare|Biotechnology|USA

$23.35

-0.82 (-3.39%)

Tangible Book

$5.20

Clinical Trials (10)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT04871282 A Study of AL102 in Patients With Progressing Desmoid Tumors	Desmoid, Desmoid Tumor	P2P3	Active	198	RCT, Double-blind	AL102
NCT06823167 A Phase 1 Study of IM-1021 in Participants With Advanced Cancer	Solid Malignancies, Hematologic Malignancies	P1	Recruiting	117	Open-label	IM-1021
NCT07610005 A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants	Healthy	P1	Recruiting	20	RCT, Open-label	Varegacestat Reference Formulation, Varegacestat Test Formulation
NCT07578571 A Phase 1 Study of IM-1617 in Participants With Advanced Cancer	Colorectal Cancer, Non-Small Cell Lung Cancer	P1	Recruiting	175	Open-label	IM-1617
NCT07505771 A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer	Solid Malignancies	Early P1	Recruiting	105	Open-label	177Lu-IM-3050
NCT06841315 A Varegacestat Hepatic Impairment Study	Healthy Volunteer, Hepatic Impairment (HI)	P1	Completed	35	Open-label	varegacestat
NCT06855264 A Cardiac Liability Study of Varegacestat in Healthy Participants	Healthy Volunteer	P1	Completed	32	RCT, Double-blind	varegacestat, Placebo, Moxifloxacin 400 mg
NCT06677996 A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants	Healthy Volunteer	P1	Completed	22	Open-label	varegacestat, Itraconazole (200 mg)
NCT06845852 A Phase 1 Mass Balance Study of Varegacestat	Healthy Volunteer	P1	Completed	6	Open-label	varegacestat
NCT05429021 IMM-BCP-01 in Mild to Moderate COVID-19	SARS-CoV2 Infection, COVID-19	P1	Terminated	9	RCT, Double-blind	IMM-BCP-01, Placebo